ISPOR Europe 2026 News Center
Explore the news and reporting from ISPOR Europe 2026 in the News Center with curated stories on cutting-edge topics from the conference.
ISPOR Europe 2026 Daily Round-Ups: Insights From Day 1
2026/11/10 | The Evidence Base
ISPOR 2026 Speakers Call for a Soft Revolution to Turn Innovation Into Real-World Value
2026/11/10 | Navlin Daily
Experts Weigh in MFN Impact on Drug Launches and Access
2026/11/10 | Navlin Daily
Your Guide to ISPOR Europe 2026
2026/11/08 | The Evidence Base
As AI Becomes More Autonomous, Where Does Human Oversight Need to Remain? Sessions on the Agenda at ISPOR Europe 2026
2026/11/05 | The Evidence Base
Can Europe Protect Access and Innovation as Global Pricing Policies Collide? Sessions on the Agenda at ISPOR Europe 2026
2026/11/05 | The Evidence Base
Is the Definition of Value in Healthcare Changing? Sessions on the Agenda at ISPOR Europe 2026
2026/11/05 | The Evidence Base
What Will It Take for RWE to Become Decision-Grade? Sessions on the Agenda at ISPOR Europe 2026
2026/11/05 | The Evidence Base
One Year Into JCA, What Have We Learned and What Comes Next? Sessions on the Agenda at ISPOR Europe 2026
2026/11/05 | The Evidence Base
ISPOR Europe 2026: Shaping the Future of Access Through Science and Policy
ISPOR 2026 Speakers Call for a Soft Revolution to Turn Innovation Into Real-World Value [Navlin Daily]
ISPOR Europe 2026 Daily Round-Ups: Insights From Day 1 [The Evidence Base]
Experts Weigh in MFN Impact on Drug Launches and Access [Navlin Daily]
The Learning Is Underway at #ISPOREurope! A summary of the Short Course Program at ISPOR Europe. [LinkedIn]
Can Europe Protect Access and Innovation as Global Pricing Policies Collide? Sessions on the Agenda at ISPOR Europe 2026 [The Evidence Base]
Is the Definition of Value in Healthcare Changing? Sessions on the Agenda at ISPOR Europe 2026 [The Evidence Base]
As AI Becomes More Autonomous, Where Does Human Oversight Need to Remain? Sessions on the Agenda at ISPOR Europe 2026 [The Evidence Base]
One Year Into JCA, What Have We Learned and What Comes Next? Sessions on the Agenda at ISPOR Europe 2026 [The Evidence Base]
Your Guide to ISPOR Europe 2026 [The Evidence Base]
Understanding the Use of AI in the RWE Research Lifecycle: What is the Evidence Telling Us? [The Evidence Base]
What Will It Take for RWE to Become Decision-Grade? Sessions on the Agenda at ISPOR Europe 2026 [The Evidence Base]
From Defining Value to Reshaping Evidence: What to Expect From the ISPOR Europe 2026 Plenary Sessions [The Evidence Base]
ISPOR Europe 2026 Plenaries Announced [ISPOR]
Looking Ahead to ISPOR Europe 2026: HEOR Heads to Vienna [The Evidence Base]
EU HTA Update: Medical Device JCAs Move Forward as Fourth Medicinal Product Assessment Is Discontinued [The Evidence Base]
A Dual Mandate for Branded Drug Prices [The Evidence Base]
Understanding the Use of AI in the RWE Research Lifecycle: Why a Living Scoping Review is Needed [The Evidence Base]
Validating LLM-Derived RWD Across Borders: Extending the VALID Framework to UK Prostate Cancer Data [The Evidence Base]
A Dual Mandate for Branded Drug Prices [The Evidence Base]
Photo Gallery
Additional News From the Conference
15 Years at ISPOR Europe: SCHARR Showcases Research Excellence [University of Sheffield]
A Study in the Federal District Is Monitoring 1345 Patients with Adrenal Insufficiency in the Brazilian Public Health System / Estudo do DF acompanha 1.345 pacientes com insuficiência adrenal no SUS [Bsb1]
AI Methods and Safety at ISPOR Europe 2026 [NICE]
Research from the Federal District Selected for Conference in Austria / Pesquisa do Distrito Federal é Selecionada Para Congresso na Áustria [Agita Brasilia]
Genesis Research Group Launches Keystone Evidence Planning Platform at ISPOR Europe 2026 [Deal Room]
OHE Featured Sessions at ISPOR Europe 2026 [OHE]
Medaffcon and EasyHTA Develop New Tools for Health Economic Assessment [Medaffcon]
Flatiron Health Announces Research at ISPOR Europe 2026 Advancing Global Oncology Evidence for Health Technology Assessment [Business Wire]
Leveraging Clinical Notes to Uncover Evidence of Alcohol Use Disorder Missed by Diagnosis Codes Alone [Norstella]
P95 Julius Clinical Becomes AKEURA, a Specialist CRO in Clinical Development and Real-World Evidence [Fidelity]
Pilot Evaluation: EvidenceAi™ Suite vs Human First Drafts [Evidence Mastery]
Medaffcon Posters at ISPOR: New Insights into Cancer Care and Technology-Assisted Homecare [Medaffcon]
The Data Isn’t the Problem. Your Study Design Might Be [TriNetX]
Mind the Gap (and close it at ISPOR Europe in Vienna): New Assessment Rules Are Testing the Limits of Observational Evidence [Adigens Health]
Fitness for Purpose: Why “Is This Data Good?” Gets Data Quality Wrong [TriNetX]
NVHPF Considers Impacts of International Reference Pricing in U.S. Drug Pricing Models [Applied Policy]
F2G Announces Posters Accepted for Presentation at Upcoming Medical Meetings [Yahoo!Finance]
Veradigm Examines Pre-Diagnostic Gaps in Testicular Cancer Assessment for Young Men [Traders Union]
The Economic Case for Every New Branded Drug Has to Be Proved [Edgemont]
HEOR News Desk
ISPOR News Webpage
Thank You to ISPOR Europe 2026 Media Partners:
A special thank you to the ISPOR Europe 2026 Media Partners—Clinical Leader, Clinical Tech Leader, Life Science Leader, Journal of Medical Economics, and The Evidence Base—and to all the media outlets who are reporting on the conference.
Disclaimer:
The reporting on ISPOR Europe 2026 from external news sources reflects the views of the authors/media outlets and is not endorsed by ISPOR.